JP2006504404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504404A5 JP2006504404A5 JP2004508843A JP2004508843A JP2006504404A5 JP 2006504404 A5 JP2006504404 A5 JP 2006504404A5 JP 2004508843 A JP2004508843 A JP 2004508843A JP 2004508843 A JP2004508843 A JP 2004508843A JP 2006504404 A5 JP2006504404 A5 JP 2006504404A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- sensitivity
- bacterial strain
- use according
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 13
- 239000004599 antimicrobial Substances 0.000 claims description 11
- 230000001131 transforming effect Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 8
- 108010015899 Glycopeptides Proteins 0.000 claims 5
- 102000002068 Glycopeptides Human genes 0.000 claims 5
- 108010059993 Vancomycin Proteins 0.000 claims 4
- 210000002421 cell wall Anatomy 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960003165 vancomycin Drugs 0.000 claims 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 3
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 3
- 229930182555 Penicillin Natural products 0.000 claims 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 3
- 108010053950 Teicoplanin Proteins 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 102000006635 beta-lactamase Human genes 0.000 claims 3
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229960003085 meticillin Drugs 0.000 claims 3
- 229940049954 penicillin Drugs 0.000 claims 3
- 229960001608 teicoplanin Drugs 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 206010011409 Cross infection Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 2
- 206010029803 Nosocomial infection Diseases 0.000 claims 2
- 241000295644 Staphylococcaceae Species 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 claims 2
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940124587 cephalosporin Drugs 0.000 claims 2
- 150000001780 cephalosporins Chemical class 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 244000000059 gram-positive pathogen Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical group N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims 2
- 229960001019 oxacillin Drugs 0.000 claims 2
- -1 phenyloxycarbonyl Chemical group 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 150000003952 β-lactams Chemical class 0.000 claims 2
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 claims 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical group NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 claims 1
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 claims 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229960004567 aminohippuric acid Drugs 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 229960003326 cloxacillin Drugs 0.000 claims 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- LFAVEINQLWIXRA-UHFFFAOYSA-N ethyl 2-[(2-aminoacetyl)amino]acetate Chemical compound CCOC(=O)CNC(=O)CN LFAVEINQLWIXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960004273 floxacillin Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212622.5A GB0212622D0 (en) | 2002-05-31 | 2002-05-31 | Bacterial transforming agent |
| PCT/GB2003/002402 WO2003101488A1 (en) | 2002-05-31 | 2003-06-02 | Bacterial transforming agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006504404A JP2006504404A (ja) | 2006-02-09 |
| JP2006504404A5 true JP2006504404A5 (https=) | 2007-01-11 |
Family
ID=9937806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508843A Withdrawn JP2006504404A (ja) | 2002-05-31 | 2003-06-02 | 細菌の形質転換剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060040871A1 (https=) |
| EP (1) | EP1553981A1 (https=) |
| JP (1) | JP2006504404A (https=) |
| AU (1) | AU2003232352A1 (https=) |
| BR (1) | BR0311482A (https=) |
| CA (1) | CA2487597A1 (https=) |
| EA (1) | EA007093B1 (https=) |
| GB (1) | GB0212622D0 (https=) |
| IL (1) | IL165433A0 (https=) |
| MX (1) | MXPA04011879A (https=) |
| NO (1) | NO20045680L (https=) |
| NZ (1) | NZ537447A (https=) |
| WO (1) | WO2003101488A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009036121A1 (en) * | 2007-09-12 | 2009-03-19 | Targanta Therapeutics Corp. | Method of inhibiting clostridium difficile by administration of oritavancin |
| AU2010313228B2 (en) * | 2009-10-30 | 2014-05-29 | Biogenic Innovations, Llc | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| US9839609B2 (en) | 2009-10-30 | 2017-12-12 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
| DE102010013587A1 (de) * | 2010-03-31 | 2011-10-06 | Heliolux Gmbh | N-(Aminoacyl)-Amino-Ester |
| WO2012106469A2 (en) * | 2011-02-01 | 2012-08-09 | New York University | Methods for treating infections by targeting microbial h2s-producing enzymes |
| HRP20200101T1 (hr) | 2014-11-06 | 2020-04-03 | Xellia Pharmaceuticals Aps | Glikopeptidni pripravci |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| WO2018237268A1 (en) * | 2017-06-22 | 2018-12-27 | Brown University | Novel antibacterial compounds and methods of making and using same |
| US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834430A (en) * | 1995-05-31 | 1998-11-10 | Biosynth S.R.L. | Potentiation of antibiotics |
| US6569830B1 (en) * | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
-
2002
- 2002-05-31 GB GBGB0212622.5A patent/GB0212622D0/en not_active Ceased
-
2003
- 2003-06-02 JP JP2004508843A patent/JP2006504404A/ja not_active Withdrawn
- 2003-06-02 CA CA002487597A patent/CA2487597A1/en not_active Abandoned
- 2003-06-02 AU AU2003232352A patent/AU2003232352A1/en not_active Abandoned
- 2003-06-02 IL IL16543303A patent/IL165433A0/xx unknown
- 2003-06-02 NZ NZ537447A patent/NZ537447A/en unknown
- 2003-06-02 BR BR0311482-1A patent/BR0311482A/pt not_active IP Right Cessation
- 2003-06-02 WO PCT/GB2003/002402 patent/WO2003101488A1/en not_active Ceased
- 2003-06-02 EP EP03756069A patent/EP1553981A1/en not_active Withdrawn
- 2003-06-02 MX MXPA04011879A patent/MXPA04011879A/es unknown
- 2003-06-02 EA EA200401589A patent/EA007093B1/ru unknown
- 2003-06-02 US US10/517,359 patent/US20060040871A1/en not_active Abandoned
-
2004
- 2004-12-28 NO NO20045680A patent/NO20045680L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7245289B2 (ja) | 細菌感染症の処置方法 | |
| Bush et al. | Taking inventory: antibacterial agents currently at or beyond phase 1 | |
| DK1879655T3 (en) | Pharmaceutical composition comprising an antibacterial agent and an active substance selected from carveol, carvacrol, alpha-ionone, beta-ionone, and thymol | |
| TWI690317B (zh) | 用於治療抗藥性細菌感染之組合療法 | |
| JP7121954B2 (ja) | 抗細菌性薬剤併用物の組成物及び使用方法 | |
| JP5469511B2 (ja) | 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用 | |
| CA2383522A1 (en) | Neurotherapeutic composition and method | |
| Leone et al. | Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci | |
| KR100900208B1 (ko) | 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물 | |
| JP2006504404A5 (https=) | ||
| JPH08505868A (ja) | クラブラン酸のみまたは他のベータ−ラクタム抗生物質と混合されたクラブラン酸からなる薬剤処方 | |
| MX2011002185A (es) | Composiciones y metodos de tratamiento que comprenden ceftarolina. | |
| Bergogne-Berezin | Cefpodoxime proxetil in upper respiratory tract infections | |
| CN115581700A (zh) | 质量稳定抑菌活性高的含头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 | |
| JP2002500189A5 (https=) | ||
| Butler et al. | Natural product inspired antibiotics approved for human use–1943 to 2025 | |
| ES2428167T3 (es) | Composición farmacéutica bactericida activa anti-MRSA conteniendo carbapenemos | |
| JP2015536949A (ja) | 細菌感染症のための抗生物質を用いる方法および組成物 | |
| US20060040871A1 (en) | Bacterial transforming agent | |
| Karchmer | Fluoroquinolone treatment of skin and skin structure infections | |
| US20040176349A1 (en) | Antibacterial composition | |
| US7153826B2 (en) | Treatment of rosacea | |
| JP2010505744A (ja) | 細菌感染治療の改善された方法 | |
| US20210369675A1 (en) | Antimicrobial drug methods of use & therapeutic compositions | |
| AU2014200107B2 (en) | Compositions and methods of treatment comprising ceftaroline |